Resources

New data presented yesterday for the first time at the 42nd annual meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen demonstrated a mean reduction in A1C of 2.1% from a mean baseline A1C of 8.8% and a reduction of 2.9% for those with a mean …

Levemir improves glucose control without weight gain and hypoglycemia.

Washington University researchers have developed a potential cure for Type 2 diabetes.

A new form of insulin which is inhaled rather than injected works even if patients have a respiratory infections or are exposed to passive cigarette smoke.

Preliminary blinded results from it’s Phase IIa trial with E1-I.N.T. showed 3 of the first 4 type I diabetes patients had a 35-75% reduction in daytime insulin usage following a 28 day treatment.

Studies in animals suggest that brown seaweed, also known as wakame — commonly used to flavor Asian soups and salads, contains a compound that promotes weight loss. The compound, called fucoxanthin, also has anti-diabetes effects.

Actos® (pioglitazone HCl), an oral antidiabetic medication, demonstrated significant cardiovascular benefits in reducing the risk of heart attack and/or stroke and acute coronary syndrome in patients with type 2 diabetes.

While glucagon secretion is normally triggered by hypoglycemia and inhibited as glucose levels rises, it has now been shown that very high glucose levels paradoxically stimulate glucagon secretion

Researchers have made a breakthrough which could eventually help prevent people developing diabetes.

Amylin Pharmaceuticals, announced positive results from a recent 16-week study evaluating the safety and efficacy of adding SYMLIN®) (pramlintide acetate) to an established regimen of basal insulin glargine (with or without oral antidiabetic agents) in patients with type 2 diabetes who have not progressed to mealtime insulin therapy.